DivestmentJul 6, 2026, 05:07 PM
Clarivate to Sell Life Sciences & Healthcare Business for $600M
AI Summary
Clarivate Plc has agreed to sell its Life Sciences and Healthcare business to an affiliate of Altaris, LLC for an aggregate purchase price of $600 million. The consideration includes $500 million in cash, $25 million in deferred consideration, and a $75 million unsecured senior note. The transaction is expected to close by the end of 2026, subject to regulatory approvals. Additionally, a retention agreement was entered into with Henry Levy, President of the divested business, ensuring full vesting of his unvested restricted stock units upon the transaction's closing.
Key Highlights
- Clarivate to sell its Life Sciences and Healthcare business.
- Aggregate purchase price is $600,000,000.
- $500,000,000 cash payable upon closing.
- Deferred consideration of $25,000,000.
- Unsecured senior note of $75,000,000.
- Transaction expected to close by end of calendar year 2026.
- Retention agreement for Henry Levy, President of divested unit.
- Buyer secured equity and debt financing commitments.
Price Impact
More from CLVT